Jaime R. Merchán, MD, discusses the future treatment of patients with advanced renal cell carcinoma.
Jaime R. Merchán, MD
Advertisement
Articles by Jaime R. Merchán, MD
Jaime R. Merchán, MD, discusses the current roles for immunotherapy and TKIs in patients with renal cell carcinoma.
Jaime R. Merchán, MD, discusses the role of pembrolizumab plus axitinib or lenvatinib in previously untreated advanced renal cell carcinoma.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Daratumumab and Hyaluronidase Plus VRd for Newly Diagnosed Multiple Myeloma
2
PD-L1 Expression Is More Predictive of Response to Pembrolizumab on Metastatic Sites in High-Grade Serous Ovarian Cancer
3
Dr Braunstein on the FDA Approval of Subcutaneous Daratumumab With VRd For Newly Diagnosed Multiple Myeloma
4
Ixazomib-Containing Combinations Signal Potential for More PI-Based Regimens in R/R Multiple Myeloma
5